Biogen's revenue grew 11% year over year in the third quarter, while non-GAAP earnings per share declined 46%, including $284 million of acquired in-process research and development expense. Management narrowed its full-year guidance for underlying EPS to $15.95-$16.75 from $15.85-$16.85.
Biogen remains a significant player in the $20 billion global MS market with Vumerity, Avonex, Plegridy, Tysabri, and Tecfidera, although its portfolio has been declining due to competitive pressures from newer drugs and loss of exclusivity events.
Biogen's MS portfolio is under pressure from newer branded drugs as well as generic and biosimilar versions of its older therapies.
|
Metric
|
BIIB
|
SNY
|
|---|---|---|
Price/Earnings (Normalized) | 26.67 | 12.60 |
Price/Book Value | 1.98 | 1.29 |
Price/Sales | 3.66 | 1.81 |
Price/Cash Flow | 12.52 | 7.70 |
|
Metric
|
BIIB
|
SNY
|
|---|---|---|
Quick Ratio | 0.95 | 0.21 |
Current Ratio | 1.95 | 1.12 |
Interest Coverage | 2.10 | 9.10 |
|
Metric
|
BIIB
|
SNY
|
|---|---|---|
Return on Assets (Normalized) | 5.75% | 8.44% |
Return on Equity (Normalized) | 9.42% | 15.62% |
Return on Invested Capital (Normalized) | 7.39% | 12.02% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|<SC#%Vq | LOCK|^m# | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|<?#qt@! | LOCK|@V | $658B | |||
| AbbVie Inc
ABBV
| LOCK|rf>D%R | LOCK|!pB | $521B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|?B%<@nP | LOCK|&#^ | $391B | |||
| Merck & Co Inc
MRK
| LOCK|&^>Mk@ | LOCK|$# | $369B | |||
| Novartis AG ADR
NVS
| LOCK|VH#C>P^C | LOCK|f@ | $307B | |||
| AstraZeneca PLC
AZN
| LOCK|YYJnB#ww | LOCK|B>@ | $290B | |||
| Amgen Inc
AMGN
| LOCK|<@dFgr< | LOCK|<^ | $252B | |||
| Gilead Sciences Inc
GILD
| LOCK|NQY@DYF | LOCK|#P | $212B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|P&$$R$ | LOCK|SRp | $176B |
United States